Making the undruggable druggable
Unlocking challenging drug targets for the development of next-generation therapeutics
Selected Collaborations
It all starts with the drug target.
The majority of drug targets are so-called membrane proteins, and these are inherently unstable and challenging to investigate. Or so they were, until now.
Our proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies or small molecule drugs. Through our in-house and partnered pipelines, we drive the discovery of novel drugs.
Pushing drug development forward together
We work with top-tier pharma and biotech partners to unlock drug targets for drug development programs.
Pipeline
We are driving forward drug development in our partnered as well as internal pipelines.
News
Press Release: Salipro Biotech Announces Publication in Nature Scientific Reports on Expanding DEL Screening to Membrane Proteins
2026-06-30
Study demonstrates application of DNA-Encoded Library screening to native-like membrane protein targets with the Salipro® platform.
Stockholm, Sweden, June 30, 2026 — Salipro Biotech AB today announced the publication of a study in Nature Scientific Reports describing an approach that enables DNA-Encoded Library (DEL) screening on membrane proteins using its proprietary Salipro® platform. The results can be accessed at https://rdcu.be/fqS8q.
The study was conducted in collaboration with researchers from i.a. AstraZeneca, DyNAbind, and the University of Copenhagen, demonstrating how the Salipro technology supports high-throughput screening of membrane proteins in a native-like, detergent-free environment.
The work establishes a technical proof-of-concept for applying DEL screening to complex membrane proteins and illustrates how maintaining native-like conditions supports more reliable identification of functional ligands.
By integrating the Salipro platform with DEL platforms, the approach delivers a scalable solution for identifying functional ligands against previously intractable targets. The findings highlight the potential to expand DEL screening into new areas of pharmacologically relevant biology and support more reliable hit discovery.
Salipro to Attend BIO International Convention 2026
2026-06-02
Salipro Biotech will be in San Diego for the BIO International Convention 2026 (June 22 - 25).
Our Business Development Director, Peter Jahnmatz, will be on site to connect with partners and discuss opportunities where the Salipro® platform enables drug discovery projects against complex targets such as GPCRs, ion channels or transporters.
Attending BIO?Connect with Peter via the BIO Partnering system to book a meeting and explore how we can unlock difficult drug targets for your drug discovery programs.
We look forward to engaging with both new and existing partners at BIO International 2026!
Find more information about the conference: https://convention.bio.org/
Invited speaker from Salipro at Discovery & Development Europe 2026
2026-05-26
Salipro Biotech is heading to Discovery & Development Europe 2026 (June 15-16), happening in Berlin, Germany!
Will you be there?
Join our CEO Jens Frauenfeld on stage, on Tuesday June 16 at 14:50, who will present how the Salipro® platform enables advanced DEL-based discovery and validation of native ion channel modulators.
In addition, our Scientist Mia Abramsson will be presenting a poster during the conference.
Interested in drug discovery towards complex membrane protein targets or the Salipro® platform? Let’s connect in Berlin!